Sanofi
SNY
$47.13
-$0.30-0.63%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -15.09% | -13.22% | |
| Total Other Revenue | -- | -- | 33.83% | 30.52% | |
| Total Revenue | -- | -- | -12.27% | -10.71% | |
| Cost of Revenue | -- | -- | -9.88% | -6.79% | |
| Gross Profit | -- | -- | -13.30% | -12.39% | |
| SG&A Expenses | -- | -- | -22.87% | -18.19% | |
| Depreciation & Amortization | -- | -- | -16.67% | -5.66% | |
| Other Operating Expenses | -- | -- | 79.87% | 90.45% | |
| Total Operating Expenses | -- | -- | -6.76% | -2.97% | |
| Operating Income | -- | -- | -31.60% | -36.92% | |
| Income Before Tax | -- | -- | -59.12% | -53.73% | |
| Income Tax Expenses | -- | -- | -69.51% | -67.83% | |
| Earnings from Continuing Operations | -- | -- | -56.46% | -50.20% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | 67.81% | 69.70% | |
| Net Income | -- | -- | -49.87% | -43.75% | |
| EBIT | -- | -- | -31.60% | -36.92% | |
| EBITDA | -- | -- | -24.08% | -27.56% | |
| EPS Basic | -- | -- | -49.88% | -43.75% | |
| Normalized Basic EPS | -- | -- | -- | -55.37% | |
| EPS Diluted | -- | -- | -49.95% | -43.82% | |
| Normalized Diluted EPS | -- | -- | -- | -55.37% | |
| Average Basic Shares Outstanding | -- | -- | -0.09% | -0.07% | |
| Average Diluted Shares Outstanding | -- | -- | 0.10% | 0.03% | |
| Dividend Per Share | -- | -- | 11.29% | 11.29% | |
| Payout Ratio | -- | -- | -- | -- | |